Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting Phase II NCT07662122

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight — Active Not Recruiting • Phase II • Diabetes /…

📅 29 Sep 2026 ⏱ 2 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Phase II
NCT ID
NCT07662122
Start
2026-06-30
Completion
2027-06-26
ClinicaliQ Trial Snapshot
  • A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight — Active Not Recruiting • Phase II • Diabetes / Metabolic • NCT07662122.
  • Trial testing whether BI 3034701 injection helps weight loss in obese/overweight adults over ten months.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This study is open to adults between 18 and 74 years of age and who have a body mass index (BMI) of 30 kg/m2 or more, or a BMI of 27 kg/m2 or more and at least 1 health problem related to their weight. People who have previously not managed to lose weight by changing their diet can participate. People with type 2 diabetes cannot take part in this study. The purpose of this study is to find out whether a medicine called BI 3034701 helps people living with obesity…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Semaglutide for Managing Overweight and Obesity (NICE TA875)
Diabetes / Metabolic · 27 Mar 2026
Initiate semaglutide only in specialist obesity services or via shared care with clear primary-secondary care protocols for adults with BMI ≥30 kg/m²…
View guideline →
Guideline
Tirzepatide for Managing Overweight and Obesity (NICE TA1026)
Diabetes / Metabolic · 27 Mar 2026
Prescribe tirzepatide to adults with BMI ≥35 kg/m² or BMI 30–34.9 kg/m² with weight-related comorbidities, initiating treatment in specialist weight management services…
View guideline →
Clinical Brief
New light shed on who benefits most from weight-loss jabs
Diabetes / Metabolic · BBC Health · 08 Apr 2026
People who carry variations in two genes linked to appetite and digestion can lose more weight when taking drugs to treat obesity,…
View brief →
Clinical Brief
Daily pill to help keep weight off after stopping obesity jabs
Diabetes / Metabolic · BBC Health · 12 May 2026
Orforglipron is a daily oral tablet offering an alternative to GLP-1 receptor agonist injections for weight maintenance after obesity treatment cessation The…
View brief →
Clinical Brief
Why weight-loss jabs work better for some people than others
Diabetes / Metabolic · BBC Health · 10 Apr 2026
Genetic variations in appetite and digestion genes predict differential weight-loss responses to GLP-1 receptor agonists (Wegovy, Mounjaro), suggesting personalised medicine approaches may…
View brief →
Guideline
Non-Alcoholic Fatty Liver Disease: Assessment and Management (NICE NG49)
Diabetes / Metabolic · 27 Mar 2026
Use FIB-4 or NAFLD Fibrosis Score in primary care to stratify fibrosis risk in adults with metabolic risk factors (type 2 diabetes,…
View guideline →